Experimental drug INCB000631 put to first safety test in humans
NCT ID NCT07039929
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 37 times
Summary
This early-stage study tested the safety and how the body handles the experimental drug INCB000631 in 24 healthy adults. Participants received either the drug or a placebo by mouth. The trial was terminated, so final results may not be available. It was not designed to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Celerion, Inc
Lincoln, Nebraska, 68502, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCB000631
What could go wrong
This is a very early, small study in healthy people, so it cannot show whether the drug works for any disease. The trial was terminated, meaning results may be incomplete.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.